Cited by 248Extracellular vesicles in diseaseCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology Research

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer

Open access
Yang, Sujuan, Che, Sara P. Y., Kurywchak, Paul, Tavormina, Jena L., Gansmo, Liv B., Correa de Sampaio, Pedro, Tachezy, Michael, Bockhorn, Maximilian +5 more·2017·Cancer Biology & Therapy

Abstract

Pancreatic cancer presents with a dismal mortality rate and is in urgent need of methods for early detection with potential for timely intervention. All living cells, including cancer cells, generate exosomes. We previously discovered double stranded genomic DNA in exosomes derived from the circulation of pancreatic cancer patients, which enabled the detection of prevalent mutations associated with the disease. Here, we report a proof-of-concept study that demonstrates the potential clinical utility of circulating exosomal DNA for identification of KRASG12D and TP53R273H mutations in patients with pancreas-associated pathologies, including pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis (CP) and intraductal papillary mucinous neoplasm (IPMN), and in healthy human subjects. In 48 clinically annotated serum samples from PDAC patients, digital PCR analyses of exosomal DNA identified KRASG12D mutation in 39.6% of cases, and TP53R273H mutation in 4.2% of cases. KRASG12D and TP53R273H mutations were also detected in exosomal DNA from IPMN patients (2 out of 7 with KRASG12D, one of which also co-presented with TP53R273H mutation). Circulating exosomal DNA in 5 out of 9 CP patients enabled the detection of KRASG12D mutation. In 114 healthy subject-derived circulating exosomal DNA, 2.6% presented with KRASG12D mutation and none with TP53R273H mutation. This study highlights the value of circulating exosomal DNA for a rapid, low-cost identification of cancer driving mutations. The identification of mutations in IPMN patients and healthy subjects suggests that liquid biopsies may allow potential assessment of cancer risk but with a cautionary note that detection of clinical cancer cannot be assumed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15384047.2017.1281499

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liquid biopsy using circulating cfDNA is valuable for diagnosis and monitoring in pancreatic cancer.

    “In pancreatic cancer, liquid biopsy using circulating cfDNA proves valuable for diagnosis and monitoring.”

    From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [30]

    The Discussion says emerging studies suggest circulating cfDNA could be used for cancer diagnosis and monitoring, and it reports mutation detection in pancreatic cancer patients. But the claim's 'proves valuable' is stronger than that tentative statement: this paper tests exosomal DNA, does not establish cfDNA's clinical value for monitoring pancreatic cancer, and cautions that detecting a mutation does not necessarily signify disease. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • KRASG12D and TP53R273H mutations were detected in exosomal DNA from PDAC patients, showing potential role of liquid biopsy.

    “A study successfully detected KRASG12D and TP53R273H mutations in exosomal DNA from PDAC patients, showcasing the potential role of liquid biopsy [30].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yang, S., Che, S. P. Y., Kurywchak, P., Tavormina, J. L., Gansmo, L. B., Correa de Sampaio, P., Tachezy, M., Bockhorn, M., Gebauer, F., Haltom, A. R., Melo, S. A., LeBleu, V. S., & Kalluri, R.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • University Medical Center Hamburg-Eppendorf (DE)
  • Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal (I3S)
Corresponding author
Kalluri, Raghu
Venue
Cancer Biology & Therapy
Published
2017-01-25
Volume
18
Issue
3
Pages
158-165
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W2582660163
Cited by
248
References
42
Citations by year
2026: 15 · 2025: 14 · 2024: 24 · 2023: 27 · 2022: 26 · 2021: 37 · 2020: 38 · 2019: 33 · 2018: 20 · 2017: 13 · 2016: 1
FWCI
11.62
Type
journal article
Language
en
Open access
Locations
  • Cancer Biology & Therapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Texas MD Anderson Cancer Center ((CA016672))
  • National Cancer Institute (P30CA016672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
circulating exosomes, exosomal DNA, KRAS G12D mutation, pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm, chronic pancreatitis, liquid biopsy, early cancer detection, cancer risk assessment, digital PCR
MeSH terms
DNA, DNA, Neoplasm, Humans, Mutation, Pancreatic Neoplasms, Case-Control Studies, Polymerase Chain Reaction, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review